BIIB -7% after saying its experimental Alzheimer's drug diranersen missed the main goal of its mid-stage study, which tested whether higher
BIIB -7% after saying its experimental Alzheimer's drug diranersen missed the main goal of its mid-stage study, which tested whether higher doses provided greater benefit in patients with early Alzheimer's Disease; said the drug, however, slowed decline in memory, thinking and daily functioning in the trial (more)
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.